AU2001239392A1 - Inflammation-inducible hybrid promoters, vectors containing same and uses thereof - Google Patents

Inflammation-inducible hybrid promoters, vectors containing same and uses thereof

Info

Publication number
AU2001239392A1
AU2001239392A1 AU2001239392A AU3939201A AU2001239392A1 AU 2001239392 A1 AU2001239392 A1 AU 2001239392A1 AU 2001239392 A AU2001239392 A AU 2001239392A AU 3939201 A AU3939201 A AU 3939201A AU 2001239392 A1 AU2001239392 A1 AU 2001239392A1
Authority
AU
Australia
Prior art keywords
inflammation
vectors containing
containing same
hybrid promoters
promoters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239392A
Inventor
Francis Berenbaum
Gilbert Bereziat
Charbel Massaad
Jean-Luc Olivier
Colette Salvat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0003262A external-priority patent/FR2806418B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001239392A1 publication Critical patent/AU2001239392A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Abstract

The invention concerns gene expression regulating and is based particularly on the use of constructs enabling to activate transcription of a transgene in cells, tissues or organs in inflammatory condition. The inventive promoters preferably contain: a) an element of response to a PPAR and b) all or part of a promoter of gene PLA2sIIA. The invention also concerns vectors, cells and compositions comprising said promoters and their use for regulating expression of genes in vitro, ex vivo or in vivo.
AU2001239392A 2000-03-14 2001-03-14 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof Abandoned AU2001239392A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0003262A FR2806418B1 (en) 2000-03-14 2000-03-14 HYBRID INFLAMMATION INDUCIBLE PROMOTERS, VECTORS CONTAINING THEM, AND USES
FR0003262 2000-03-14
US19695900P 2000-04-13 2000-04-13
US60196959 2000-04-13
PCT/FR2001/000759 WO2001068845A2 (en) 2000-03-14 2001-03-14 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof

Publications (1)

Publication Number Publication Date
AU2001239392A1 true AU2001239392A1 (en) 2001-09-24

Family

ID=26212255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239392A Abandoned AU2001239392A1 (en) 2000-03-14 2001-03-14 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof

Country Status (9)

Country Link
EP (1) EP1263978B1 (en)
JP (1) JP2003526368A (en)
AT (1) ATE312187T1 (en)
AU (1) AU2001239392A1 (en)
CA (1) CA2403189A1 (en)
DE (1) DE60115610T2 (en)
DK (1) DK1263978T3 (en)
ES (1) ES2254378T3 (en)
WO (1) WO2001068845A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269897A (en) * 1992-08-13 1994-02-23 Merck Frosst Canada Inc Assay to detect peroxisome proliferator activity
FR2755699B1 (en) * 1996-11-08 1998-12-18 Rhone Poulenc Rorer Sa NEW CONSTRUCTIONS AND VECTORS FOR TARGETED AND INDUCTIBLE GENE EXPRESSION
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
CZ20014609A3 (en) * 1999-06-22 2002-05-15 Aventis Pharma S. A. Composition containing nucleic acid encoding PPAR nuclear receptor and user thereof for expression control

Also Published As

Publication number Publication date
WO2001068845A2 (en) 2001-09-20
DK1263978T3 (en) 2006-04-18
CA2403189A1 (en) 2001-09-20
ATE312187T1 (en) 2005-12-15
WO2001068845A3 (en) 2002-02-28
DE60115610D1 (en) 2006-01-12
DE60115610T2 (en) 2006-10-19
JP2003526368A (en) 2003-09-09
ES2254378T3 (en) 2006-06-16
EP1263978B1 (en) 2005-12-07
EP1263978A2 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
WO1997014809A3 (en) Novel expression vectors and methods of use
GB2353282A (en) Control of gene expression
EP0452269A3 (en) Tissue-preferential promoters
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
AU2001264166A1 (en) Vector constructs
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
WO2001094394A3 (en) Plant ubiquitin promoter sequences and methods of use
AU2002230691A1 (en) Putrescine-n-methyltransferase promoter
EP1792982A3 (en) Codon-optimised alkaline phosphatase and its expression in yeast
WO2008095027A3 (en) Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
AU2003239823A1 (en) Optimization of transgene expression in mammalian cells
EP1070122A4 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
HK1043812A1 (en) Mammalian expression vectors containing exogenous 5'-untranslated region as a transcription requlatory element
WO2004033653A3 (en) Gene regulation with aptamer and modulator complexes for gene therapy
AU4835696A (en) Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
AU2001239392A1 (en) Inflammation-inducible hybrid promoters, vectors containing same and uses thereof
WO1997005260A3 (en) An expression control sequence for general and effective expression of genes in plants
AU2003260200A1 (en) Reversible, parallel and multitask cloning method and kit
AU1165400A (en) Novel system for regulating transgene expression
WO2002046220A3 (en) Sequences upstream of the carp gene, vectors containing them and uses thereof
ATE355385T1 (en) PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRUS GENE BANKS
DE60334222D1 (en) Adenovirusvektor
WO1999027123A3 (en) Modified sv40 viral vectors
WO2003089596A3 (en) Novel prostate tumor-specific promoter